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Abstract
Background: Immunodeficiency Centromeric Instability and Facial anomalies (ICF) is a rare autosomal recessive
disease characterized by reduction in serum immunoglobulins with severe recurrent infections, facial dysmorphism,
and more variable symptoms including mental retardation. ICF is directly related to a genomic methylation defect
that mainly affects juxtacentromeric heterochromatin regions of certain chromosomes, leading to chromosomal
rearrangements that constitute a hallmark of this syndrome upon cytogenetic testing. Mutations in the de novo
DNA methyltransferase DNMT3B, the protein ZBTB24 of unknown function, or loci that remain to be identified, lie at
its origin. Despite unifying features, common or distinguishing molecular signatures are still missing for this disease.
Method: We used the molecular signature that we identified in a mouse model for ICF1 to establish transcriptional
biomarkers to facilitate diagnosis and understanding of etiology of the disease. We assayed the expression and
methylation status of a set of genes whose expression is normally restricted to germ cells, directly in whole blood
samples and epithelial cells of ICF patients.
Results: We report that DNA hypomethylation and expression of MAEL and SYCE1 represent robust biomarkers, easily
testable directly from uncultured cells to diagnose the most prevalent sub-type of the syndrome. In addition, we
identified the first unifying molecular signatures for ICF patients. Of importance, we validated the use of our biomarkers
to diagnose a baby born to a family with a sick child. Finally, our analysis revealed unsuspected complex molecular
signatures in two ICF patients suggestive of a novel genetic etiology for the disease.
Conclusions: Early diagnosis of ICF syndrome is crucial since early immunoglobulin supplementation can improve the
course of disease. However, ICF is probably underdiagnosed, especially in patients that present with incomplete
phenotype or born to families with no affected relatives. The specific and robust biomarkers identified in this study
could be introduced into routine clinical immunology or neurology departments to facilitate testing of patients with
suspected ICF syndrome. In addition, as exemplified by two patients with a combination of molecular defects never
described before, our data support the search for new types of mutations at the origin of ICF syndrome.
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Background
Immunodeficiency with centromeric instability and facial
anomalies (ICF; OMIM no. 242860) is a rare autosomal
recessive disorder mainly characterized by primary im-
munodeficiency [1]. Recurrent infections are the present-
ing symptom, usually in early childhood. Other features
include mild facial anomalies and variable symptoms in-
cluding intellectual disability, congenital malformations
and developmental delay [2].
ICF syndrome is a genetically heterogeneous disease with
heterogeneous molecular defects and phenotypic variability
(Reviewed in [3]). Around 60% of patients (ICF1) have mu-
tations in the catalytic domain of the de novo DNA methyl-
transferase (DNMT) DNMT3B [4-6] leading to reduced
enzymatic activity [7,8] associated with a significant loss of
DNA methylation, notably at juxtacentromeric satellite
repeats on chromosome 1 and 16, and less frequently 9
(Reviewed in [9]). The remainder have either non-sense
mutations in the zinc-finger and BTB domain-containing
24 (ZBTB24) gene (ICF2) [10] or no identifiable mutation
in either DNMT3B or ZBTB24 coding sequences (ICFX)
[11]; both ICF2 and ICFX show hypomethylation of centro-
meric alpha-satellites (α-Sat) in addition to the above men-
tioned repeats [12]. Hypomethylation of satellite repeats is
associated with centromeric instability and constitutes an
invariant molecular hallmark of ICF patients. Chromosomal
anomalies are detectable by karyotype analysis of mitogen-
stimulated lymphocytes and that is used to establish the
diagnosis [13,14].
Data obtained in ICF lymphoblastoid cell lines (LCLs)
showed that DNMT3B mutations also lead to hypome-
thylation and perturbed expression of several hundred of
genes involved in immune function, development and
neurogenesis, being both up- and down-regulated, which
probably account for the phenotypical manifestations
documented in patients [15-17]. Additional molecular
mechanisms acting in trans, such as perturbed nuclear
organization as a result of the altered juxtacentromeric or
telomeric heterochromatin organization [18-20], deregu-
lated expression of small regulatory microRNAs (miRNA)
[21] or changes in replication timing [22] may also have a
deep impact on the deregulation of gene expression pro-
grams in ICF patients. However, these perturbed profiles
showed great variability, probably reflecting phenotypic
variability between patients and cell culture effects, and
no common or distinguishing molecular signatures could
be reliably established from these studies.
Our analysis of perturbed DNA methylation patterns
and expression programs in a mouse model for ICF1 re-
vealed the striking over-representation of germline genes
among the most upregulated genes [23]. In addition, our
data suggested a new role for Dnmt3b in the protection
of somatic cells against the promiscuous expression of
the germ line program, playing the central role in both
the establishment and maintenance of DNA methylation
profiles at these genes [24]. Although the impact of their
illicit expression on ICF phenotypes remains to be solved,
their inherent repressed state in all somatic cells makes
them good candidate biomarkers of molecular dysfunc-
tions in ICF syndrome. We tested hypomethylation and
illicit expression of the thus identified germline genes in a
cohort of ICF patients that included five newly enrolled
patients, in order to establish a molecular signature easily
testable directly from the blood of ICF patients.
Material and methods
This study was conducted in accordance with the Helsinki
Declaration, with informed consent obtained from each
patient or the patient’s family. The study was approved by
the local ethics committee of Necker-Enfants Malades
Hospital, Paris, France.
An expanded Methods section for DNA methylation and
gene expression analysis can be found in Additional file 1.
Healthy donors and patients
Blood samples of six healthy volunteers, aged 35, 24, 26,
27, 29 and 41 years, respectively, were collected and were
numbered from 1 to 6. Donors 3 and 6 are women.
Our cohort of patients included thirteen ICF1 patients
with mutations in DNMT3B, six ICF2 patients with mu-
tations in ZBTB24 and four ICFX patients with as of yet
unknown mutations (Additional file 2). Most patients were
described earlier [11,12,25-27] except for five newly en-
rolled patients (Table 1). The ICF B-lymphoblastoid and
fibroblasts named here pCor were obtained from the
Coriell Cell Repositories (USA) (http://ccr.coriell.org/).
Patients pG, pR, pI, pH, pC, pD, pN, pP, pS were recruited
by the ICF Consortium and described together with pa-
tients pG, pR, pI, pH, pC, pD, pN, pP, pS in [12]. Patients
pW, pT and P5 were described earlier [11,25,26]. Patients
P7 and P8 were recently classified as ICF2 patients [27].
Patients pC, pS, pU and pN were classified as ICFX pa-
tients since sequence analysis of DNMT3B and ZBTB24
genes performed as previously described [12,27] did not
reveal any mutation in their coding sequences.
New ICF syndrome patients P1, P2, P3, P4 and pY
were diagnosed according to cytogenetic analysis that
revealed typical multiradial chromosome configurations
with multiple arms from chromosomes 1 and 16, and
clinical features, mainly primary immunodeficiency. For
these patients, primary immunodeficiency and hypome-
thylation at satellite repeats are detailed in Additional
files 3 and 4. These patients were classified as ICF1 pa-
tients (Necker Hospital, Paris, France) based on mutations
found in DNMT3B using previously described sequencing
methods [12,27]. Written informed consent was obtained
from the parents of the patients.
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Primary cells and cell lines
Primary fibroblasts (passage 7 for pG, pW and pT; passage
5 for pR; passage 6 for pI; passage 14 for pC and pP; pas-
sage 9 for pCor and pS) and Lymphoblastoid cell lines
(LCLs) from healthy donors and ICF patients were cultured
in DMEM and RPMI 1640 respectively, supplemented with
15% FCS, glutamine and antibiotics (Invitrogen).
Methylation-sensitive restriction enzyme-coupled qPCR assay
Genomic DNA (200 ng) was digested at 37°C for 4 h
with 10 U of the methylation-sensitive enzyme AciI, or
NcoI (New England Biolabs) which does not have cutting
sites in our regions of interest and served to normalize
the data. The endonucleases were subsequently inacti-
vated by incubation at 65°C for 20 min. Real-time PCR
was carried out using the light cycler-DNA MasterPLUS
SYBR Green I mix (Roche) supplemented with 0.5 μM
specific primer pairs and with 2 μL of digested DNA.
Real-time quantification PCR were run on a light cycler
rapid thermal system (LightCycler®480 2.0 Real time PCR
system, Roche) with 20 sec of denaturation at 95°C,
20 sec of annealing at 65°C and 20 sec of extension at
72°C for all primers, and analyzed by the comparative
CT (∆CT) method according to the formula: methylation
(%) = E(∆CT) × 100 where E represents PCR efficiency and
∆CT =CTsample (AciI digest) - CTsample (NcoI digest). Se-
quences of primers within CpG islands at germline gene
promoters are shown in Additional file 1. Each data
shown on histograms is the mean result of qPCR analysis
on at least three independent experiments performed on
at least three independent genomic extractions.
Results and discussion
Hypomethylation and expression of MAEL and SYCE1
define molecular markers for ICF1 syndrome
Peripheral blood samples were obtained from healthy do-
nors and ICF patients. We assessed profiles of gene ex-
pression focusing on the germline genes transcriptional
signature that we previously established in a mouse model
for ICF1 [23,24].
As expected from their expression primarily in germ
cells (Additional file 5; and RNAseq and exon arrays data-
sets on normal tissues publically available at UCSC gen-
ome browser) and function in meiosis, expression of the
germline genes tested was undetectable in blood cells
from healthy controls, although that of SYCE1 showed
some degree of variation between healthy donors that
did not seem to correlate with age or sex (Figure 1 and
Additional file 6). In contrast, strong expression was de-
tected for two of them in blood cells from ICF patients;
among all the germline genes tested, only that of MAEL-
STROM (MAEL), involved in repression of transposable
elements during meiosis, and Synaptonemal Complex
Central Element Protein 1 (SYCE1), involved in assembly
of the synaptonemal complex during meiosis in germ
cells, were transcribed in blood cells from ICF patients
(Figure 1 and Additional files 6 and 7). This illegitimate
expression in whole blood was very strong and remarkably
specific for ICF1 patients while at significantly lower levels
in ICF2 blood cells (raw data and p values in Additional
file 6). Interestingly, patient P5 had only mild ICF pheno-
type [25] although he showed strong expression of MAEL
and SYCE1. Therefore, given their repressed state in nor-
mal somatic tissues, detection of MAEL and SYCE1 ex-
pression in blood cells provides a statistically significant
signature for the most prevalent sub-type of the disease,
regardless of the severity of the symptoms.
Since the germline genes tested in this study are known
to be repressed through DNA methylation in mice
[23,24,28] we analyzed their methylation status on genomic
DNA isolated from fresh whole blood samples (Figure 2A)
or epithelial cells obtained from buccal swabs (Figure 2B),
from ICF patients and healthy donors. Consistent with their
expression only in blood cells from ICF1 patients (Figure 1),
analysis of methylation at MAEL and SYCE1 revealed their
hypomethylated state specifically in ICF1 patients since
ICF2 and ICFX patients (except ICFX patient pN; discussed
below) were methylated at values comparable to healthy
controls (raw data and p values in Additional file 8). Simi-
larly, Solute Carrier family 25 member 31 (SLC25A31 also
known as ANT4), encoding a mitochondrial ADP/ATP
carrier essential during spermatogenesis, was signifi-
cantly hypomethylated only in ICF1 patients (Figure 2 and
Additional file 8) although this hypomethylation did not
correlate with transcriptional activation (Additional file 6).
Importantly, and as mentioned above, this transcriptional
signature could not have been unraveled using classically
available cultured patient cells like Epstein-Barr virus-
transformed lymphoblastoid cell lines (LCLs) and primary
fibroblasts. Indeed, although we could easily detect MAEL
Table 1 Genetic characteristics of newly identified ICF1 patients
Patients P1 P2 P3* P4* pY
Year of birth 2010 2008 2009 2013 1996
Gender F M F F M
Amino acid changes in DNMT3B (NP_008823.1) p. S655L/ ? p. R104X/p. I721T p. G583S/p. G583S p. G583S/p. G583S p.T775I/p.T775I
Consanguinity NO NO YES YES YES
M: male; F: female; *siblings.
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and SYCE1 transcripts in these cultured cells, this expres-
sion was independent of patient genotype (Additional
file 7). We also noticed that the illicit expression of
MAEL in fibroblasts from ICF1 patients became un-
detectable beyond passage 9 (Additional file 9), although
DNA methylation levels at its promoter remained rela-
tively unchanged, suggesting that extensive culture may
limit findings of illegitimately expressed genes. Hypo-
methylation of DNMT3B-target genes in ICF2 and
ICFX cells (Additional file 7), in which DNMT3B is not
mutated, could result from well-known, direct or indirect,
aberrant culture-induced defects of DNA methylation
[29]. Furthermore, EBV transformation and cell culture
perturb DNA methylation patterns in human LCLs, in
particular at satellite repeats of juxtacentromeric regions
[30] that are used to diagnose ICF patients. Therefore, like
in previously reported transcriptomic studies examining
differential gene expression profiles between ICF patients
and healthy controls [15,16], our data obtained in LCLs or
fibroblasts probably reflected culture-associated defects in
DNA methylation and gene expression, which have been
superimposed on the intrinsic defects that affect patients,
and do not allow the reliable identification of biomarkers
with diagnostic value.
In contrast, the analysis that we conducted in uncul-
tured cells from patients provided the first blood-based
gene expression test to identify ICF1 syndrome, and the
first discriminating transcriptional differences amongst
ICF patients. The molecular functions of ZBTB24 remain
to be identified, but the finding that the germline genes
tested herein are not similarly affected by mutations in
DNMT3B or ZBTB24 contradicts earlier suggestion that
ZBTB24 is a mere adapter of DNMT3B function [12].
Hypomethylation signature common to patients with
mutations in DNMT3B or ZBTB24
DNA methylation at the promoters of DEAD (Asp-Glu-
Ala-Asp) Box Polypeptide 4 (DDX4), the homolog of
VASA proteins in Drosophila with key roles in germ cells
development, and Testis Expressed 12 (TEX12), was simi-
lar between patients and controls, suggesting that, in con-
trast to the mouse, methylation of these genes was not
affected in human DNMT3B- or ZBTB24-deficient cells
(Additional file 10). Interestingly, the Synaptonemal
Complex Protein 1 (SYCP1) gene showed significant hy-
pomethylation in all but one ICFX patient with unknown
mutation. Similarly, we observed hypomethylation of the
X-linked testis-expressed gene 11 (TEX11) irrespective of
ICF subtype (Figure 2; black bars), but restricted to female
ICF cells (raw data and p values in Additional file 8).
Whether hypomethylation at SYCP1 and TEX11 pro-
moters was a direct consequence of ZBTB24 loss of integ-
rity remains to be seen. However, these data identifies
SYCP1 and TEX11 as the first unique gene loci affected by
ZBTB24 mutations and contribute to a significant pro-
gress in our understanding of the etiology of ICF syn-
drome. In the case of the X-linked gene TEX11, it is likely
related to the global hypomethylation of the inactive
X-chromosome reported in female ICF1 patients [31,32].
Therefore, the hypomethylation of SYCP1 and TEX11
(Figure 2 and Additional file 8) regardless of the ICF sub-
type represents the first unifying molecular signature for
ICF syndrome and suggests that hypomethylation of the
inactive X-chromosome in female patients may represent
an invariant feature of ICF syndrome. In addition, these
data point to a putative role of ZBTB24 in establishment
or maintenance of DNA methylation at the inactive
X-chromosome.
A new molecular heterogeneity among ICF patients
The perturbations that we reported here represent a reli-
able index of DNMT3B dysfunction in ICF1 patients,
with the notable exception of patient pN. Based on our
predictions of a molecular signature that varies accord-
ing to ICF genotype, the germline methylation (Figure 2)
and expression (Figure 1) signatures that we found in
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Figure 1 Expression of MAEL and SYCE1 in whole blood defines specific biomarkers for ICF1 patients. Expression levels of MAEL (purple
bars) and SYCE1 (green bars) were assessed by qRT-PCR, normalized to U6 snRNA levels and presented as fold change relative to that of control
whole blood from healthy donors (WB). ICF subtypes 1 and 2 are indicated and separated by dotted lines. Raw data used to built this Figure can
be found in Additional file 6. WB, control whole blood from healthy donors. Error bars represent standard error.
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ICFX patient pN would place this patient in the ICF1
subtype. However, no mutation was previously found in
the coding regions of DNMT3B for this patient [12] or
in a new sequencing of DNMT3B and ZBTB24 exons.
Intriguingly, the ICFX patient pN differs from other ICFX
patients in that this patient had some degree of hypome-
thylation at α-Sat repeats, intermediate between hypome-
thylation found in ICF2 cells and almost full methylation
characteristic of normal and ICF1 cells (Additional file 4).
In addition, this profile resembles that of patient P1, first
classified as ICF1 because of mutations in DNMT3B ma-
ternal allele but for whom no mutation could be found in
the coding regions of the paternal allele. The combination
of hypomethylation at MAEL and SYCE1 germline genes,
indicative of DNMT3B impaired activity, with modest but
reproducible hypomethylation at α-Sat repeats, which is
never observed in ICF1 patients and was instrumental in
suggesting genetic heterogeneity among ICF patients, im-
plies an even more complex genetic etiology for these two
patients. In the absence of an identified “culprit gene” for
these patients, it remains unclear whether a third locus is
implicated in ICF syndrome. Alternatively, these patients
could be “compound” heterozygotes for mutations in both
DNMT3B and ZBTB24, though it would have to be out-
side coding regions since exome sequencing did not reveal
any mutation in the exons of any of the two genes. The
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Figure 2 Relative DNA methylation levels at germline gene promoters in whole blood and buccal swabs from ICF patients. Methylation
analysis in whole blood (A) and buccal swabs (B) were assessed by Methylation-Sensitive Restriction Assay, followed by qRT-PCR amplification of
the AciI digested product with primers flanking at least two AciI sites within the promoter CpG island. A non-cutter NcoI control digest served to
normalize data that are presented as a percentage of methylation relative to the control digest. ICF subtypes 1, 2, and X are indicated and separated
by dotted lines. For the X-linked gene TEX11, female patients are indicated as black bars. Raw data used to built this Figure can be found in Additional
file 8. WB and BS are control whole blood DNA and buccal swabs from healthy donor, respectively. Error bars represent standard error.
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genetic defects in these patients will be probably highly in-
formative from a mechanistic perspective regarding the
establishment and maintenance of DNA methylation pat-
terns. These observations also emphasize that additional
molecular markers besides the methylation of α-Sat se-
quences are required to distinguish various classes of ICF
patients.
Expression and methylation of germline genes to
diagnose individuals with suspected ICF syndrome
We propose that profiling of DNA methylation at MAEL
and SYCE1 germline genes, combined to the detection
of their illicit expression using non-invasive diagnostic
techniques, could serve as a powerful, quick, and simple
procedure to diagnose patients with suspected ICF1 syn-
drome. Because these genes are normally repressed in
somatic tissues, any diagnostic test based on their expres-
sion will give an unambiguous result. To test the power of
these genes for diagnostic means, we assessed methylation
and expression profiles of germline genes in a child born
to a consanguineous family but whose genotype at the
time of testing was not known. This child, who is a sibling
of patient P3, was born during the course of this study,
and we were able to sample buccal epithelial cells and per-
ipheral blood when she was 3 months old. Our analysis
revealed germline gene methylation and transcription pro-
files typical of that of ICF1 patients tested in this study
(Figure 3 and p values in Additional file 8). These observa-
tions were highly suggestive of the ICF1 syndrome in this
child, who we named patient P4 (Table 1). In line with our
predictions, diagnosis of the ICF1 syndrome was subse-
quently confirmed by sequencing of DNMT3B exons and
characterization of the same mutations identified in her
older sister (Table 1).
Conclusions
Correlations between genotype and phenotype of ICF
patients are emerging [11], and the defining of a reliable
ICF-specific molecular signatures will help to explain such
differences in the clinical manifestations of ICF syndrome
amongst ICF patient subtypes. In addition to providing a
new contribution to the characterization of unifying and
distinguishing molecular signatures between ICF patient
subtypes, this first molecular signature identifiable in the
peripheral blood or epithelial cells of patients could be eas-
ily introduced into routine clinical immunology or neur-
ology departments to facilitate testing of patients with
suspected ICF syndrome. Because ICF is probably under-
diagnosed, we predict that the analysis of such markers will
greatly aid diagnosis and prioritize patients for mutation
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Figure 3 Hypomethylation coupled to illegitimate expression of MAEL and SYCE1 to diagnose ICF1 syndrome. Uncultured cells from a
child born to a consanguineous family with one sick children were used to test the power of these biomarkers. Methylation analysis (A and B) at
germline gene promoters indicated on the right was carried out as in Figure 2, from whole blood (A) and buccal swabs (B). Expression analysis
of MAEL and SYCE1 (C), the only germline genes to be transcriptionally activated upon hypomethylation, was performed from whole blood
samples as in Figure 1. The newborn, a sibling of P3, is now patient P4 after the ICF syndrome was confirmed by sequencing of DNMT3B alleles.
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from healthy donor; Errors bars represent standard error.
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screening in cases where performing exome-sequencing or
cytogenetics analysis may represent a challenge or when
ICF should be suspected like in patients with immunodefi-
ciency as the presenting factor if associated with facial
anomalies [33], in patients that present an incomplete ICF
phenotype or individuals from consanguineous families
[25], or newborns from families where ICF cases have
already been reported (this study). In addition, our analysis
allowed the identification of unprecedented molecular char-
acteristics in two ICF patients, suggestive of a novel type of
genetic origin for the disease, stressing the need to continue
the search for mutations that lead to immunodeficiency as-
sociated with chromosomal instability. The hallmark of ICF
being hypomethylation of heterochromatin DNA repeats,
combined, these efforts will have great impact on our un-
derstanding of the DNA methylation pathways.
Additional files
Additional file 1: Additional methods section for DNA methylation
and gene expression analysis. Table of primers used for PCR amplification.
Additional file 2: Table summarizing genetic mutations found in
ICF patients already described and associated references.
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